These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 8244657)

  • 21. Sustained improvement of performance and haemodynamics with long-term aerosolised prostacyclin therapy in severe pulmonary hypertension.
    Stricker H; Domenighetti G; Fiori G; Mombelli G
    Schweiz Med Wochenschr; 1999 Jun; 129(24):923-7. PubMed ID: 10413827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Continuous intravenous epoprostenol in pulmonary hypertension: the Israel experience.
    Bendayan D; Fink G; Aravot D; Ygla M; Bendov I; Bliden L; Nir A; Kramer MR
    Isr Med Assoc J; 2002 Apr; 4(4):255-8. PubMed ID: 12001697
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unpredictable response to vasodilator therapy in primary pulmonary hypertension.
    Schmiedt MI; Shettigar UR; Siddique M; Barbier G; Bialow M; Carranza S
    Int J Clin Pharmacol Ther; 1998 Aug; 36(8):435-40. PubMed ID: 9726697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin.
    Barst RJ; Rubin LJ; McGoon MD; Caldwell EJ; Long WA; Levy PS
    Ann Intern Med; 1994 Sep; 121(6):409-15. PubMed ID: 8053614
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of prostacyclin in the treatment of primary pulmonary hypertension: the Cambridge experience.
    Cremona G
    Cardiologia; 1993 Dec; 38(12 Suppl 1):227-32. PubMed ID: 8020021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Continuous intravenous prostacyclin therapy].
    Miyaji K; Matsubara H
    Nihon Rinsho; 2008 Nov; 66(11):2139-44. PubMed ID: 19051733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of long-term infusion of prostacyclin on exercise performance in patients with primary pulmonary hypertension.
    Wax D; Garofano R; Barst RJ
    Chest; 1999 Oct; 116(4):914-20. PubMed ID: 10531153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical study on long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol infusion].
    Cao TS; Yuan LJ; Duan YY; Wang ZJ; Zhuang L; Shapiro SM; Brundage BH
    Zhonghua Nei Ke Za Zhi; 2003 Feb; 42(2):106-9. PubMed ID: 12783707
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin).
    Jones DK; Higenbottam TW; Wallwork J
    Br Heart J; 1987 Mar; 57(3):270-8. PubMed ID: 3552006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term prostacyclin infusion to reduce pulmonary hypertension in a pediatric cardiac transplant candidate prior to transplantation.
    Kao B; Balzer DT; Huddleston CB; Canter CE
    J Heart Lung Transplant; 2001 Jul; 20(7):785-8. PubMed ID: 11448812
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary pulmonary hypertension. An analysis of 28 cases and a review of the literature.
    Hughes JD; Rubin LJ
    Medicine (Baltimore); 1986 Jan; 65(1):56-72. PubMed ID: 2867454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension.
    Rubin LJ; Groves BM; Reeves JT; Frosolono M; Handel F; Cato AE
    Circulation; 1982 Aug; 66(2):334-8. PubMed ID: 7046988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Definition, concept and pathophysiology of pulmonary hypertension].
    Kunieda T
    Nihon Rinsho; 2001 Jun; 59(6):1037-46. PubMed ID: 11411110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension.
    Raffy O; Azarian R; Brenot F; Parent F; Sitbon O; Petitpretz P; Hervé P; Duroux P; Dinh-Xuan AT; Simonneau G
    Circulation; 1996 Feb; 93(3):484-8. PubMed ID: 8565165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension.
    Rich S; McLaughlin VV
    J Am Coll Cardiol; 1999 Oct; 34(4):1184-7. PubMed ID: 10520810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduction of acute pulmonary hypertension by prostacyclin.
    Borchert J; Franke J; Lichey J
    Cor Vasa; 1980; 22(4):281-7. PubMed ID: 7004773
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of continuous intravenous epoprostenol therapy on advanced primary pulmonary hypertension in Taiwanese patients.
    Hsu HH; Chen JS; Kuo SH; Chiang FT; Ko WJ; Kuo SW; Huang SC; Lee YC
    J Formos Med Assoc; 2005 Jan; 104(1):60-3. PubMed ID: 15660181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial.
    Rubin LJ; Mendoza J; Hood M; McGoon M; Barst R; Williams WB; Diehl JH; Crow J; Long W
    Ann Intern Med; 1990 Apr; 112(7):485-91. PubMed ID: 2107780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary pulmonary hypertension. Practical therapeutic recommendations.
    Rubin LJ
    Drugs; 1992 Jan; 43(1):37-43. PubMed ID: 1372858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension.
    Nagaya N; Uematsu M; Okano Y; Satoh T; Kyotani S; Sakamaki F; Nakanishi N; Miyatake K; Kunieda T
    J Am Coll Cardiol; 1999 Oct; 34(4):1188-92. PubMed ID: 10520811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.